GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares

September 02, 2010 | About:
insider

insider

57 followers
CEO/CSO of Progenics Pharmaceuticals Inc. (PGNX) Paul J Maddon buys 5,000 shares of PGNX on 09/01/2010 at an average price of $4.1 a share.

Progenics Pharmaceuticals Inc. has a market cap of $135.4 million; its shares were traded at around $4.18 with and P/S ratio of 2.8. Progenics Pharmaceuticals Inc. had an annual average earning growth of 5.6% over the past 10 years.

PGNX is in the portfolios of Paul Tudor Jones of The Tudor Group, Jim Simons of Renaissance Technologies LLC.

This is the annual revenues and earnings per share of PGNX over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of PGNX.


CEO Recent Trades:



  • Buy: CEO/CSO Paul J Maddon bought 5,000 shares of PGNX stock on 08/02/2010 at the average price of 4.75. Paul J Maddon owns at least 834,057 shares after this. The price of the stock has decreased by 12% since.
  • Buy: CEO/CSO Paul J Maddon bought 5,000 shares of PGNX stock on 07/16/2010 at the average price of 4.99. Paul J Maddon owns at least 829,057 shares after this. The price of the stock has decreased by 16.23% since.
  • Buy: CEO/CSO Paul J Maddon bought 5,000 shares of PGNX stock on 06/01/2010 at the average price of 4.99. Paul J Maddon owns at least 824,057 shares after this. The price of the stock has decreased by 16.23% since.
  • Buy: CEO/CSO Paul J Maddon bought 5,000 shares of PGNX stock on 05/20/2010 at the average price of 4.93. Paul J Maddon owns at least 819,057 shares after this. The price of the stock has decreased by 15.21% since.


CFO Recent Trades:



  • Sell: CFO Robert A Mckinney sold 4,000 shares of PGNX stock on 06/18/2010 at the average price of 6.25. Robert A Mckinney owns at least 32,925 shares after this. The price of the stock has decreased by 33.12% since.



This is the insider trade history vs. stock price of PGNX. For the complete insider trading history of PGNX, click here.




Directors and Officers Recent Trades:



  • Sell: VP, Research & Development William C Olson sold 2,364 shares of PGNX stock on 06/22/2010 at the average price of 5.81. William C Olson owns at least 35,494 shares after this. The price of the stock has decreased by 28.06% since.
  • Sell: Sr. VP, Medical Affairs Robert J Israel sold 6,180 shares of PGNX stock on 06/22/2010 at the average price of 5.82. Robert J Israel owns at least 31,186 shares after this. The price of the stock has decreased by 28.18% since.
  • Sell: Sr. VP, Product Dev. Thomas A Boyd sold 2,409 shares of PGNX stock on 06/22/2010 at the average price of 5.74. Thomas A Boyd owns at least 36,625 shares after this. The price of the stock has decreased by 27.18% since.
  • Sell: President Mark Robert Baker sold 2,328 shares of PGNX stock on 06/22/2010 at the average price of 5.66. Mark Robert Baker owns at least 26,689 shares after this. The price of the stock has decreased by 26.15% since.
  • Sell: Sr. VP, Medical Affairs Robert J Israel sold 7,056 shares of PGNX stock on 03/18/2010 at the average price of 5.37. Robert J Israel owns at least 36,842 shares after this. The price of the stock has decreased by 22.16% since.


  • CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
  • Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
  • Double Buys:: Companies that both Gurus and Insiders are buying
  • Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.

» Take a Free Trial of Premium Membership

About the author:

insider
GuruFocus - Stock Picks and Market Insight of Gurus

Rating: 3.4/5 (5 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK